From pharmaceuticals to innovation in Europe: in 2015 French-born Sylvie Bove was named CEO of EIT Health, the first European initiative to promote European leadership and competitiveness in health innovation. Bove has 20 years experience managing and directing companies in the field of life sciences. She has overseen the launch of new products while working with large companies in the healthcare sector, such as Coloplast and Ferring Pharmaceuticals, and she helped found the Copenhagen Healthtech Cluster.
Executive Vice President for International Affairs at the Biotechnology Innovation Organization (BIO)
Mr. Damond is responsible for developing and implementing the industry association’s international advocacy and outreach program, including the areas of trade policy and foreign government relations. Prior to taking up this position at BIO, Mr. Damond was vice president for International Government Relations in Pfizer’s Washington office from 2006-2011.
Edward Kliphuis joined the previous biopharma fund MS Ventures in 2014 and transitioned to Investment Director New Businesses. Previously, Edward was at Kempen & Co, a pan-European merchant bank based in Amsterdam, where he was on the Life Sciences Securities team. He was instrumental in the team’s ongoing fundraising efforts for listed European small- and mid-cap biotech companies in over 20 deals in 2012 and 2013. Edward holds an MSc in Biopharmaceutical Sciences from Leiden University, the Netherlands, specializing in pharmacology and science-based business.